September 28 | 2021
Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain
Read more
August 26 | 2021
2cureX publishes interim report for the second quarter and first half of 2021
Read more
August 20 | 2021
New development of the IndiTreat® technology allows prediction of response to anti-angiogenic drugs in colorectal cancer.
Read more
July 29 | 2021
2cureX appoints two internationally highly recognized oncologists as Clinical Advisors
Read more
July 19 | 2021
2cureX receives important ISO 13485:2016 certification
Read more
July 1 | 2021
2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer
Read more
June 22 | 2021
2cureX appoints 2 new VPs for its Commercial Operations
Read more
June 7 | 2021
ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients
Read more
June 4 | 2021
REDEYE releases an updated 2cureX Equity Research Report
Read more
June 1 | 2021
Management exercise all warrants within the framework of the 2018 incentive program
Read more
May 27 | 2021
2cureX publishes interim report for the first quarter of 2021
Read more
May 27 | 2021
Communiqué from the Annual General Meeting of 2cureX AB
Read more
May 20 | 2021
2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting
Read more
May 11 | 2021
Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million.
Read more
May 6 | 2021
Mangold Fondkommission AB published an Analyst Report on 2cureX
Read more
May 6 | 2021
2cureX publishes the annual report for the fiscal year 2020
Read more
April 27 | 2021
2cureX’s CEO Fernando Andreu is buying shares in the company
Read more